PCSK9 and atherosclerosis: A large number of clinical trials have investigated the lipid-lowering effect and clinical benefit of mAbs to PCSK9 in many categories of patients with hypercholesterolaemia or established atherosclerotic cardiovascular disease (ASCVD), proving their efficacy and safety [25–27].